Anti-incretin, Anti-Proliferative action of dopamine on B-Cells

Molecular Endocrinology

Volumn 29, Issue 4, 2015, Pages 542-557

  Maffei, Antonella ^a,b   Segal, Ann Marie ^a   Alvarez Perez, Juan Carlos ^c   Garcia Ocaña, Adolfo ^c   Harris, Paul E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CASPASE 3; CASPASE 7; DOPAMINE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; INSULIN; LEVODOPA; LIRAGLUTIDE; SOMATOSTATIN 14; GLUCOSE BLOOD LEVEL; SOMATOSTATIN;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; INSULIN RELEASE; INTRACELLULAR SIGNALING; MALE; MONOTHERAPY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RAT; TEST MEAL; TRANSLATIONAL RESEARCH; ADULT; ANIMAL; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PANCREAS ISLET; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

RATTUS; RODENTIA;

ADULT; ANIMALS; BLOOD GLUCOSE; CELL LINE; CELL PROLIFERATION; DOPAMINE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN;

EID: 84926364033     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1273     Document Type: Article

References (95)

1. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring). 2013;21(6):1093-1103
2. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724-1737
3. Pories WJ, MacDonald KG Jr, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up.AmJ Clin Nutr. 1992;55(2 suppl):582S-585S
4. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55(7):2025-2031
5. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252(6):966-971
6. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-350; discussion 350-332
7. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467-484; discussion 484-485
8. Rubino F, R’bibo SL, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol. 2010;6(2):102-109
9. Simpson N, Maffei A, Freeby M, et al. Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitro. Mol Endocrinol. 2012;26(10):1757-1772
10. Ustione A, Piston DW. Dopamine synthesis and D3 receptor activation in pancreatic b-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations. Mol Endocrinol. 2012;26(11):1928-1940
11. Raffo A, Hancock K, Polito T, et al. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. J Endocrinol. 2008;198(1):41-49
12. Ustione A, Piston DW, Harris PE. Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet. Mol Endocrinol. 2013;27(8):1198-1207
13. Rubí B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2- like receptors are expressed in pancreatic b cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280(44):36824-36832
14. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci. 2004;27(5):270-277
15. Shankar E, Santhosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life. 2006;58(3):157-163
16. García-Tornadú I, Ornstein AM, Chamson-Reig A, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology. 2010;151(4):1441-1450
17. Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab. 1997;82(11):3864-3871
18. Vieira-Coelho MA, Soares-da-Silva P. Dopamine formation, from its immediate precursor 3,4-dihydroxyphenylalanine, along the rat digestive tract. Fundam Clin Pharmacol. 1993;7(5):235-243
19. Iturriza FC, Thibault J. Immunohistochemical investigation of tyrosine- hydroxylase in the islets of Langerhans of adult mice, rats and guinea pigs. Neuroendocrinology. 1993;57(3):476-480
20. Kozicz T, Arimura A. Distribution of urocortin in the rat’s gastrointestinal tract and its colocalization with tyrosine hydroxylase. Peptides. 2002;23(3):515-521
21. Mezey E, Eisenhofer G, Harta G, et al. A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine. Proc Natl Acad Sci USA. 1996;93(19):10377-10382
22. Goldstein DS, Swoboda KJ, Miles JM, et al. Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab. 1999;84(7):2523-2531
23. Blum I, Vered Y, Graff E, et al. The influence of meal compositionon plasma serotonin and norepinephrine concentrations. Metabolism. 1992;41(2):137-140
24. Rask E, Olsson T, Söderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24(9):1640-1645
25. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004;145(2):667-678
26. Hansen KB, Bräuner-Osborne H. FLIPR assays of intracellular calcium in GPCR drug discovery. Methods Mol Biol. 2009;552:269-278
27. Fiaschi-Taesch NM, Kleinberger JW, Salim FG, et al. Cytoplasmicnuclear trafficking of G1/S cell cycle molecules and adult human b-cell replication: a revised model of human b-cell G1/S control. Diabetes. 2013;62(7):2460-2470
28. Cadavez L, Montane J, Alcarraz-Vizan G, et al. Chaperones ameliorate b cell dysfunction associated with human islet amyloid polypeptide overexpression. PLoS One. 2014;9(7):e101797
29. Martins LM, Mesner PW, Kottke TJ, et al. Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis. Blood. 1997;90(11): 4283-4296
30. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic b-cell death. Endocrinology. 2003;144(9):4154-4163
31. Speck M, Cho YM, Asadi A, Rubino F, Kieffer TJ. Duodenaljejunal bypass protects GK rats from b-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Am J Physiol Endocrinol Metab. 2011;300(5): E923-E932
32. Straub SG, Sharp GW. Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins. Am J Physiol Cell Physiol. 2012;302(12):C1687-C1698
33. Clarke WL, Santiago JV, Thomas L, Ben-Galim E, Haymond MW, Cryer PE. Adrenergic mechanisms in recovery from hypoglycemia in man: adrenergic blockade. Am J Physiol. 1979;236(2):E147-E152
34. Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic b-cells. Metabolism. 2014;63(1):9-19
35. Light PE, Manning Fox JE, Riedel MJ, Wheeler MB. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol. 2002;16(9):2135-2144
36. Park SW, Seo MK, Cho HY, et al. Differential effects of amisulpride and haloperidol on dopamine D2 receptor-mediated signaling in SH-SY5Y cells. Neuropharmacology. 2011;61(4):761-769
37. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998; 78(1):189-225
38. Hodson DJ, Tarasov AI, Gimeno Brias S, et al. Incretin-modulated b cell energetics in intact islets of Langerhans. Mol Endocrinol. 2014;28(6):860-871
39. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate- sensitive potassium channels. Endocr Rev. 1999;20(2):101-135
40. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999; 42(8):903-919
41. Gilon P, Henquin JC. Influence of membrane potential changes on cytoplasmic Ca2+concentration in an electrically excitable cell, the insulin-secreting pancreatic B-cell. J Biol Chem. 1992;267(29): 20713-20720
42. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104(1):1-9
43. Satin LS. New mechanisms for sulfonylurea control of insulin secretion. Endocrine. 1996;4(3):191-198
44. Zylbergold P, Ramakrishnan N, Hebert T. The role ofGproteins in assembly and function of Kir3 inwardly rectifying potassium channels. Channels (Austin). 2010;4(5):411-421
45. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24(3):165-205
46. Dalle S, Burcelin R, Gourdy P. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic b-cell impairments in type 2 diabetes. Cell Signal. 2013;25(2):570-579
47. Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF. Human b-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes. 2012;61(9):2205-2213
48. Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocaña A. Human b-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes. 2014;63(3):819-831
49. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. 2007;28(4):166-172
50. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide- 1 protects b cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48(7):1339-1349
51. Liu H, Remedi MS, Pappan KL, et al. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. Diabetes. 2009;58(3):663-672
52. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in b (INS-1)-cells. Diabetologia. 1999;42(7):856-864
53. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397-4408
54. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon- like peptide-1 receptor signaling modulates b cell apoptosis. J Biol Chem. 2003;278(1):471-478
55. Quoyer J, Longuet C, Broca C, et al. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a b-arrestin 1-mediated ERK1/2 activation in pancreatic b-cells. J Biol Chem. 2010;285(3): 1989-2002
56. Talbot J, Joly E, Prentki M, Buteau J. b-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic b INS832/13 cells. Mol Cell Endocrinol. 2012;364(1-2):65-70
57. Hupfeld CJ, Resnik JL, Ugi S, Olefsky JM. Insulin-induced b-arrestin1 Ser-412 phosphorylation is a mechanism for desensitization of ERK activation by Gai-coupled receptors. J Biol Chem. 2005; 280(2):1016-1023
58. Vasavada RC, Gonzalez-Pertusa JA, et al. Growth factors and b cell replication. Int J Biochem Cell Biol. 2006;38(5-6):931-950
59. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Cx activation mediates glucagon-like peptide-1-induced pancreatic b-cell proliferation. Diabetes. 2001;50(10):2237-2243
60. Hirai T, Chida K. Protein kinase C x (PKCx): activation mechanisms and cellular functions. J Biochem. 2003;133(1):1-7
61. Naranatt PP, Akula SM, Zien CA, Krishnan HH, Chandran B. Kaposi’s sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-x-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity. J Virol. 2003;77(2):1524-1539
62. Xie Z, Singh M, Siwik DA, Joyner WL, Singh K. Osteopontin inhibits interleukin-1b-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: role of protein kinase C-x. J Biol Chem. 2003;278(49):48546-48552
63. Mergler S, Singh V, Grötzinger C, Kaczmarek P, Wiedenmann B, Strowski MZ. Characterization of voltage operated R-type Ca2+ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells. Cell Signal. 2008;20(12):2286-2295
64. Lahlou H, Guillermet J, Hortala M, et al. Molecular signaling of somatostatin receptors. Ann NY Acad Sci. 2004;1014:121-131
65. Degtiar VE, Wittig B, Schultz G, Kalkbrenner F. A specific G(o) heterotrimer couples somatostatin receptors to voltage-gated calcium channels in RINm5F cells. FEBS Lett. 1996;380(1-2):137-141
66. Schmidt A, Hescheler J, Offermanns S, et al. Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine- sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991;266(27):18025-18033
67. Peverelli E, Olgiati L, Locatelli M, et al. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett. 2010;288(2): 170-176
68. Zitzmann K, Andersen S, Vlotides G, et al. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM- 23A758 decreases the viability of human GOT1 midgut carcinoid cells. Neuroendocrinology. 2013;98(2):128-136
69. Serrano P, Yago MD, Mañas M, Calpena R, Mataix J, Martínez- Victoria E. Influence of type of dietary fat (olive and sunflower oil) upon gastric acid secretion and release of gastrin, somatostatin, and peptide YY in man. Dig Dis Sci. 1997;42(3):626-633
70. Bykhovskaia M. Synapsin regulation of vesicle organization and functional pools. Semin Cell Dev Biol. 2011;22(4):387-392
71. Danial NN, Walensky LD, Zhang CY, et al. Dual role of proapoptotic BAD in insulin secretion and b cell survival. Nat Med. 2008; 14(2):144-153
72. Panet H, Barzilai A, Daily D, Melamed E, Offen D. Activation of nuclear transcription factor B (NF- B) is essential for dopamineinduced apoptosis in PC12 cells. J Neurochem. 2001;77(2):391-398
73. Chen XC, Zhu YG, Wang XZ, Zhu LA, Huang C. Protective effect of ginsenoside Rg1 on dopamine-induced apoptosis in PC12 cells. Acta Pharmacol Sin. 2001;22(8):673-678
74. Song JH, Slot AJ, Ryan RW, Ross GM. Dopamine-induced death of PC12 cells is prevented by a substituted tetrahydronaphthalene. Neuropharmacology. 2004;46(7):984-993
75. Chen XC, Zhu YG, Zhu LA, et al. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol. 2003;473(1):1-7
76. Lee MK, Kang SJ, Poncz M, Song KJ, Park KS. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. 2007;39(3):376-384
77. Lai CT, Yu PH. Dopamine- and L-b-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol. 1997;53(3): 363-372
78. Kondratskyi A, Kondratska K, Skryma R, Prevarskaya N. Ion channels in the regulation of apoptosis. Biochim Biophys Acta. Published online ahead of print October 27, 2014. doi:10.1016/j.bbamem. 2014.10.030
79. Fei H, Zhao B, Zhao S, Wang Q. Requirements of calcium fluxes and ERK kinase activation for glucose- and interleukin-1b-induced b-cell apoptosis. Mol Cell Biochem. 2008;315(1-2):75-84
80. Gil-Parrado S, Fernández-Montalván A, Assfalg-Machleidt I, et al. Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem. 2002;277(30):27217-27226
81. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999; 284(5412):339-343
82. Szlyk B, Braun CR, Ljubicic S, et al. A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators. Nat Struct Mol Biol. 2014;21(1):36-42
83. Arnoux JB, Damaj L, Napuri S, et al. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013;98(11):4279-4284
84. Rosati G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of longterm L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. Eur Neurol. 1976;14(3):229-239
85. Eldrup E, Richter EA. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting. Am J Physiol Endocrinol Metab. 2000;279(4):E815-E822
86. Lindqvist A, Spégel P, Ekelund M, et al. Gastric bypass improves b-cell function and increases b-cell mass in a porcine model. Diabetes. 2014;63(5):1665-1671
87. Inabnet WB, Milone L, Harris P, et al. The utility of [(11)C] dihydrotetrabenazine positron emission tomography scanning in assessing b-cell performance after sleeve gastrectomy and duodenal-jejunal bypass. Surgery. 2010;147(2):303-309
88. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.NEngl J Med. 2005;353(3):249-254
89. Weiss R. Effects of Roux-en-Y gastric bypass on b-cell function. Diabetes. 2014;63(4):1171-1173
90. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-1576
91. Keidar A, Hershkop KJ, Marko L, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for obese patients with type 2 diabetes: a randomised trial. Diabetologia. 2013;56(9):1914-1918
92. Malandrucco I, Pasqualetti P, Giordani I, et al. Very-low-calorie diet: a quick therapeutic tool to improve b cell function in morbidly obese patients with type 2 diabetes. Am J Clin Nutr. 2012;95(3): 609-613
93. Landsberg L, Taubin HL. Uptake and metabolism of L-3,4-dihydroxyphenylalanine (DOPA) in rat tissues. Biochem Pharmacol. 1973;22(22):2789-2800
94. Jiménez A, Ceriello A, Casamitjana R, Flores L, Viaplana-Masclans J, Vidal J. Remission of type 2 diabetes after Roux-en-Y gastric bypass or sleeve gastrectomy is associated with a distinct glycemic profile. Ann Surg. 2015;261(2):316-322
95. Sakano D, Shiraki N, Kikawa K, et al. VMAT2 identified as a regulator of late-stage b-cell differentiation. Nat Chem Biol. 2014; 10(2):141-148.